Retevmo, Retsevmo (selpercatinib) is a small molecule pharmaceutical. Selpercatinib was first approved as Retevmo on 2020-05-08. It is used to treat non-small-cell lung carcinoma and thyroid neoplasms in the USA. It has been approved in Europe to treat non-small-cell lung carcinoma and thyroid neoplasms. It is known to target proto-oncogene tyrosine-protein kinase receptor Ret. Retevmo's patents are valid until 2038-10-10 (FDA).
|Indication||non-small-cell lung carcinoma, thyroid neoplasms|
|Drug Class||Tyrosine kinase inhibitors|